| Overview |
| bs-2739R-Cy7 |
| PDPK1 Polyclonal Antibody, Cy7 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat, Dog, Cow, Pig, Chicken, Rabbit |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PDK1 |
| 251-350/556 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5170 |
| Cytoplasm, Cell membrane |
| 3 Phosphoinositide Dependent Protein Kinase 1; hPDK 1; PDK 1; PDPK1; PkB kinase; PkB kinase like gene 1; PkB like 1; PDPK1_HUMAN. |
| PDK1 (3 Phosphoinositide Dependent Protein Kinase 1) phosphorylates AGC kinases. PDK1 activates conventional PKC and PKC zeta through phosphorylation of critical threonine residues in the activation loop. PDK1 also phosphorylates Protein Kinase B (PKB) at threonine 308 in the presence of phosphatidylinositol-3,4,5-trisphosphate. Active Akt inactivates Glycogen Synthase Kinase 3 (GSK3), eventually leading to the dephosphorylation and activation of glycogen synthase and the stimulation of glycogen synthesis. Because of the role that PDK plays in insulin-induced glycogen synthesis and PKC activation it is a potentially important target for metabolic drug research. There are three named isoforms. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz